Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.79 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.79 |
| ▸ | LTA4H | P09960 | 2/20 | 0.63 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.57 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.57 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.57 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.54 |
| ▸ | EBP | Q15125 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | GCGR | P47871 | 1/20 | 0.52 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6592276 | 0.96 | ESR1 (0.76) | ESR1ESR2LTA4HMCHR1PSMB1 | |
| SCHEMBL4651846 | 0.93 | ESR1 (0.81) | ESR1ESR2LTA4HMCHR1PSMB1 | |
| Trioxifene SCHEMBL29464170 | 0.92 | ESR1 (0.69) | ESR1ESR2LTA4HMCHR1PSMB1 | |
| SCHEMBL11180048 | 0.92 | ESR1 (0.69) | ESR1ESR2LTA4HMCHR1PSMB1 | |
| SCHEMBL6595870 | 0.92 | ESR1 (0.83) | ESR1ESR2LTA4HMCHR1PSMB1 | |
| SCHEMBL11179589 | 0.92 | ESR1 (0.83) | ESR1ESR2LTA4HMCHR1PSMB1 | |
| Trioxifene SCHEMBL4651963 | 0.92 | ESR1 (0.69) | ESR1ESR2LTA4HMCHR1PSMB1 | |
| SCHEMBL11176566 | 0.92 | ESR1 (0.69) | ESR1ESR2LTA4HMCHR1PSMB1 | |
| SCHEMBL4650720 | 0.91 | ESR1 (0.70) | ESR1ESR2LTA4HMCHR1PSMB1 | |
| Trioxifene SCHEMBL7753024 | 0.91 | ESR1 (0.68) | ESR1ESR2LTA4HMCHR1PSMB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127440-A1 | Methods and compositions for control of bone formation via modulation of neuropeptide Y activity | BAYLOR COLLEGE OF MEDICINE | 2004-07-01 | — | — | US | claimed |
| US-20040053864-A1 | Methods and compositions for control of bone formation via modulation of neuropeptide y activity | BAYLOR COLLEGE OF MEDICINE | 2004-03-18 | — | — | US | claimed |
| EP-2002827-A2 | Methods and compositions for control of bone formation via modulation of sympathetic tone | THE BAYLOR COLLEGE OF MEDICINE (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20060165683-A1 | Methods and compositions for control of bone formation via modulation of sympathetic tone | BAYLOR COLLEGE OF MEDICINE | 2006-07-27 | — | — | US | disclosed |
| EP-1542719-A4 | METHODS AND COMPOSITIONS FOR CONTROL OF BONE FORMATION VIA MODULATION OF SYMPATHETIC TONE | BAYLOR COLLEGE MEDICINE (US) | 2006-06-21 | — | — | EP | disclosed |
| EP-1542719-A2 | METHODS AND COMPOSITIONS FOR CONTROL OF BONE FORMATION VIA MODULATION OF SYMPATHETIC TONE | THE BAYLOR COLLEGE OF MEDICINE (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040127440-A1 | Methods and compositions for control of bone formation via modulation of neuropeptide Y activity | BAYLOR COLLEGE OF MEDICINE | 2004-07-01 | — | — | US | disclosed |
| US-20040053864-A1 | Methods and compositions for control of bone formation via modulation of neuropeptide y activity | BAYLOR COLLEGE OF MEDICINE | 2004-03-18 | — | — | US | disclosed |
| WO-2003049673-A2 | METHODS AND COMPOSITIONS FOR CONTROL OF BONE FORMATION VIA MODULATION OF SYMPATHETIC TONE | BAYLOR COLLEGE OF MEDICINE (US) | 2003-06-19 | — | — | WO | disclosed |
| US-6221838-B1 | Methods of treating neuropeptide Y-associated conditions | ELI LILLY AND COMPANY | 2001-04-24 | — | — | US | disclosed |
| US-6124311-A | ADMINISTERING ONCOLYTIC AGENT WITH ENHANCED MULTIDRUG RESISTANCE REVERSING AMOUNT OF SPECIFIED COMPOUND | ELI LILLY AND COMPANY (US) | 2000-09-26 | — | — | US | disclosed |
| EP-0709090-A2 | Compositions for treating resistant tumors | ELI LILLY AND COMPANY (US) | 1996-05-01 | — | — | EP | disclosed |
| WO-1996011677-A1 | METHODS FOR TREATING RESISTANT TUMORS | ELI LILLY AND COMPANY (US) | 1996-04-25 | — | — | WO | disclosed |
| EP-0707852-A2 | Bicyclic bradykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 1996-04-24 | — | — | EP | disclosed |
| US-5491140-A | ADMINISTERING TO A MAMMAL SUFFERING FROM NERVOUS SYSTEM DISORDERS, RESPIRATORY SYSTEM DISORDERS, UROGENITAL DISORDERS ARTHRITIS, RHEUMATOID, OSTEOPROSIS, PERSISTENT PAIN, MIGRAIN OR POST-OPERATIVE PAIN | ELI LILLY AND COMPANY (US) | 1996-02-13 | — | — | US | disclosed |
| WO-1995017095-A1 | METHODS FOR THE TREATMENT OR PREVENTION OF CONDITIONS ASSOCIATED WITH AMYLOIDOGENIC REPTIDES | ELI LILLY AND COMPANY (US) | 1995-06-29 | — | — | WO | disclosed |
| WO-1995017382-A1 | NON-PEPTIDE TACHYKININ RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1995-06-29 | — | — | WO | disclosed |
| US-4400543-A | ANTIFERTILITY AGENTS | ELI LILLY AND COMPANY (US) | 1983-08-23 | — | — | US | disclosed |
| US-4323707-A | USEFUL FOR AMIMALS, AROYL-PHENYL-NAPHTHALENES OR DIHYDRONAPHTHALENES | ELI LILLY AND COMPANY (US) | 1982-04-06 | — | — | US | disclosed |
| US-4230862-A | 3-PHENYL-4-AROYL-1,2-DIHYDRONAPHTHALENES AND 1-ARYOYL-2-PHENYLNAPHTHALENES | ELI LILLY AND COMPANY (US) | 1980-10-28 | — | — | US | disclosed |